About Merus
Merus is a publicly listed company based in Utrecht (Netherlands) founded in 2003, and was acquired by Genmab in December 2025. Antibody-based drugs for cancer treatment are developed using bispecific engineering. It operates on a HealthTech model. Merus has raised $156.19 million across 11 funding rounds from investors including Pfizer, Genmab and RA Capital. The company has 260 employees. Its website merus.nl draws about 16 thousand monthly visits. Merus offers products and services including Multiclonics Platform and Clinical Trials. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Merus N.V.
Company details
Merus is engaged in the discovery and development of new cancer treatments. The company operates in the biotechnology sector, leveraging its proprietary Multiclonics Platform to create therapeutic solutions. Clinical trials are conducted to test and validate these treatments, aiming to address unmet needs in cancer care. Based in Utrecht, Netherlands, with an additional office in Cambridge, USA, Merus is committed to advancing healthcare through innovative research and development.
- Annual Revenue$36.13 M (USD)-17.78as on Dec 31, 2024
- Net Profit-$215.33 M (USD)-38.97as on Dec 31, 2024
- EBITDA-$269.6 M (USD)-75.05as on Dec 31, 2024
- Total Equity Funding$156.19M (USD)
in 11 rounds
- Latest Funding Round$15M (USD), Post-IPO
Dec 2018
- InvestorsPfizer
& 14 more
- Employee Count260
- Acquired byGenmab
(Dec 2025)
Products & Services of Merus
Merus offers a comprehensive portfolio of products and services, including Multiclonics Platform and Clinical Trials.
Innovative platform used for developing cancer treatment therapies.
Trials conducted to test new cancer treatment solutions.
Funding Insights of Merus
Merus has successfully raised a total of $156.19M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $156.19M
- Total Rounds 11
- Last Round Post-IPO — $15M
- Investors Count 14
Latest 10 of 11 funding rounds of Merus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $15M | Post-IPO | – | – | – |
| Feb 2018 | $55.8M | Post-IPO | – | – | – |
| Jan 2017 | $80M | Post-IPO | – | – | – |
| Nov 2016 | Grant | – | – | ||
| Aug 2015 | $83.82M | Series C | – | – | |
| May 2015 | Grant | – | – | ||
| Oct 2013 | $41.98M | Series B | – | – | |
| May 2011 | Grant | – | – | ||
| Jan 2010 | $30.38M | Series B | – | – | |
| Dec 2009 | $981,000 | Grant | – | – |
15 investors in total: 15 institutional.
Investors in Merus
Merus has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Genmab and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Aglaia Oncology Funds is focused on investing in oncology drug development. | 2004 | aglaia-oncology.com | Bilthoven, Netherlands | |
| eurotransbio.eu |
Investor details for Merus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Merus
125 people are tracked at Merus (62 in leadership, 12 in board & advisors, 51 in team); the tracked headcount is 260.
| Name | Role | Group |
|---|---|---|
Bill Lundberg | President, CEO, Principal Financial Officer, Executive Director | Leadership |
Brooke Esteves | Executive Director, Clinical Science | Leadership |
Shekeab Jauhari | Medical Director | Leadership |
Sejal Patel | Senior Director | Leadership |
Thomas Jaarsma | Director Finance & Accounting | Leadership |
Kimberli Brill | Executive Director Clinical Science | Leadership |
John De Kruif | SVP & Chief Technology Officer | Leadership |
Jeroen Lammerts van Bueren | Senior Director Translational Science | Leadership |
Shannon Campbell | EVP & Chief Commercial Officer | Leadership |
Cecile Geuijen | SVP & Chief Scientific Officer | Leadership |
Peter B. Silverman | EVP, COO & General Counsel | Leadership |
Jose Jaime Ferrer | Head Precision Medicine, Strategy & Commercialization | Leadership |
Sherry N. | Director Clinical Operations | Leadership |
Jaclyn Mack | Associate Director, Clinical Operations | Leadership |
Nesrine Chakroun | Director | Leadership |
Edie Wu | Executive Director Strategic Operations & Chief Of Staff | Leadership |
Anantharaghavan C. Sundararajan Itil®Expert Pmp® Safe®Agilist | Director IT Services | Leadership |
Brett Mulvey | Senior Director Field Medical Affairs | Leadership |
Patrick Corr | Director, Financial Planning And Analysis | Leadership |
Eric V. | Executive Director IT | Head Of Security And Compliance | Leadership |
105 more people are available in the full profile.
Complete people profiles for Merus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Merus
Merus is a publicly listed company on the NASDAQ with ticker symbol MRUS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jun 2016
- Listed onNASDAQ: MRUS
- Listed entityMerus N.V.
- Exchange sectorHealth technology
- ISINNL0011606264
- Share price$90.00 (-7.14% on the day) · 2025-12-31
- Market capitalisation$6.83B
- EPS (diluted, trailing year)$-5.33
- Volume (last session)2,728,675
- Analyst consensusNeutral
Financials of Merus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $36.1M | -$215.3M | -$269.6M |
| 2023 | $44.0M | -$154.9M | -$154.0M |
| 2022 | $41.6M | -$131.2M | -$158.8M |
| 2021 | $49.1M | -$66.8M | -$88.5M |
| 2020 | $29.9M | -$85.5M | -$74.4M |
Detailed financial statements for Merus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Merus
5 dated milestones of Merus across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Merus is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
- Exit Acquired by Genmab.
Web traffic of Merus
The website of Merus (merus.nl) receives about 15.7K visits a month and ranks #1,630,499 among all websites worldwide, #2,194 in Biotechnology and Pharmaceuticals.
- Monthly visits15.7K
▲ 3.5% vs previous month
- Unique visitors6.5K
per month
- Global rank#1,630,499
among all websites
- Category rank#2,194
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.9
- Average visit16 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Merus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endpts.com | 100% | 8.4K | #3,077,209 | View details | |
biochem.knu.ac.kr | biochem.knu.ac.kr | 65% | – | ||
onclive.com | onclive.com | 60% | #306,443 | – | |
| asco.org | 60% | 552.2K | #102,599 | View details | |
annalsofoncology.org | annalsofoncology.org | 60% | #169,085 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Merus
Complete news archive for Merus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merus
Merus was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Merus is headquartered in Utrecht, Netherlands.
Merus is a funded company, having raised a total of $156.19M across 11 funding rounds to date. The company's 1st funding round was a Grant of $981K, raised on Jan 2006.
Merus has 260 employees.
Annual revenue of Merus is $36.13M as on Dec 31, 2024.
Merus is engaged in the discovery and development of new cancer treatments. The company operates in the biotechnology sector, leveraging its proprietary Multiclonics Platform to create therapeutic solutions. Clinical trials are conducted to test and validate these treatments, aiming to address unmet needs in cancer care. Based in Utrecht, Netherlands, with an additional office in Cambridge, USA, Merus is committed to advancing healthcare through innovative research and development.
Merus offers Multiclonics Platform and Clinical Trials.
Yes, Merus is publicly traded on NASDAQ under the ticker symbol MRUS.
Merus has 15 investors. Key investors include Pfizer, Genmab, RA Capital, Life Sciences Partners, and Tekla Capital Management.
Merus operates through Merus N.V..
Yes. Merus was acquired by Genmab in December 2025.